Cara Therapeutics Inc
NASDAQ:CARA

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:CARA
Watchlist
Price: 18.2486 USD 243.02% Market Closed
Market Cap: 83.4m USD

Cara Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cara Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Cara Therapeutics Inc
NASDAQ:CARA
Operating Income
-$52.8m
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
-11%
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

Cara Therapeutics Inc
Glance View

Market Cap
83.4m USD
Industry
Pharmaceuticals

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

CARA Intrinsic Value
13.7344 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Cara Therapeutics Inc's Operating Income?
Operating Income
-52.8m USD

Based on the financial report for Dec 31, 2024, Cara Therapeutics Inc's Operating Income amounts to -52.8m USD.

What is Cara Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-11%

Over the last year, the Operating Income growth was 57%. The average annual Operating Income growth rates for Cara Therapeutics Inc have been 16% over the past three years , 14% over the past five years , and -11% over the past ten years .

Back to Top